Overall, we have delivered just short of 50 asset/portfolio valuations that have been used for asset licensing, company acquisition, investment negotiation and preparation for IPOs. However, we have probably done at least twice as many market opportunity analysis projects covering everything from immuno-oncology, rare diseases, cell & gene therapies, specific receptor target landscapes, point-of-care technologies, RNA platforms, CROs/CDMOs, investors, Big Pharma portfolio strategies and much more.

It is fair to say that we are Life Science generalists specialized in business development, valuation and communication in the Nordics. Our ambition is to maintain a healthy mix of long-term partnerships and shorter client engagements. We thrive when our clients succeed.